Redwood Pharma develops ophthalmic drugs in areas where medical need is especially great. This is an approach exemplified by our very first project. RP101 treats chronic dry eyes in post-menopausal women. Something that is possible thanks to our drug delivery platform IntelliGel, which controls the release of active substances. The platform also supports improved dosages of other established drugs. Dry eye disease (DED) offers enormous potential. A total of some 344 million people are affected, equivalent to a global market of USD 3.1 billion. And the market is expected to grow, not least due to the lack of effective treatments. This is something we want to change. Our strategy is to sign licence agreements with drug companies that will manufacture and market products on the global market. Redwood Pharma AB (publ.) is listed on the Nasdaq First North Growth Market (ticker: REDW, ISIN: SE008294789).